[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:hepatocellular-carcinoma:programmed-cell-death-1-ligand-1":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Hepatocellular Carcinoma","Programmed Cell Death 1 Ligand 1",5,[8,16,23,29,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07059494","Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant",[12],"Phase 4","RECRUITING","2026-08-26T02:17:32.059863Z","2026-05-05T02:43:27.947322Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04524871","A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:51.833592Z","2026-04-29T02:57:57.128598Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05919264","FOG-001 in Locally Advanced or Metastatic Solid Tumors",[20],"2026-08-26T02:19:03.581490Z","2026-07-24T01:27:14.928476Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06953089","DB-1311 in Combination With BNT327 or DB-1305 in Advanced\u002FMetastatic Solid Tumors",[33],"Phase 2","2026-08-26T02:19:18.331180Z","2026-06-16T05:54:07.929157Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT05176483","Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors",[40],"Phase 1","2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.678164Z"]